|
|
|
|
||
Pre ASCO data release - IncyteData from companies working to make a splash at ASCO is starting to emerge. Incyte is a $27B company with one approved product to treat bone marrow disorders. Their IDO inhibitor epacadostat is featured in combo with Merck and BMS checkpoint inhibitors preliminary results. Here's the link with some excepts. https://www.thestreet.com/story/14133161/1/new-incyte-ido-cancer-immunotherapy-combo-data-revealed-ahead-of -asco-17-meeting.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo "Never-before-seen data from mid-stage clinical trials combining Incyte's (INCY) IDO inhibitor epacadostat with Keytruda and Opdivo, the anti-PD-1 checkpoint inhibitors marketed by Merck (MRK) and Bristol-Myers Squibb (BMY) , respectively, have been released tonight. Incyte's shares have spiked $9.24, or 7.67%, to $129.73 in after-hours trading. Incyte and Merck have already announced an ambitious co-development program that includes five phase III studies of the epacadostat-Keytruda combination in melanoma, bladder cancer, non-small-cell lung cancer, renal (kidney) cancer and head-and-neck cancer. Here's a quick summary of the overall response rates for Incyte epacadostat-Keytruda, parsed by tumor type: Urothelial (bladder) cancer: 35% (13/37), all partial responses. Renal (kidney) cancer: 30% (9/30), one complete response, eight partial responses. Head-and-neck cancer: 31% (11/36), two complete responses, nine partial responses. Non-small cell lung cancer 35% (14/40). all partial responses. All of these combination therapy response rates are higher than what has been typically seen in PD-1 montherapy studies, suggesting the addition of epacadostat is amping up tumor shrinkage. Incyte has also hooked up with Bristol (BMS) to develop a combination therapy consisting of Incyte epacadostat and Opdivo. ASCO released a single abstract tonight describing preliminary ECHO-204 phase II data from epacadostat-Opdivo combination in a variety of tumor types. Here's a quick summary of the response rates: Head-and-neck cancer: 70% disease control rate, which combines objective tumor responses and stable disease. Melanoma: Lower dose ORR 75% (6/8), all partial responses. At higher dose, disease control rate of 64%. Ovarian cancer: 14% (4/29), all partial responses. Colon cancer: 4% (1/25), partial response." Loads of biotech princesses hoping to be big pharma checkpoint inhibitor prom dates. I think ADXS will compete favorably on cost, efficacy and safety for the cancers they are targeting in partnerships. Assuming cost, efficacy and safety plays any part in the approval and selection criteria, G.B. |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
2408 | Re: Pre ASCO data release - Incyte | terryhallinan | 0 | 5/18/2017 3:12:17 PM |